Molecular mechanisms of hexavalent chromium-induced apoptosis in human bronchoalveolar cells

American Journal of Respiratory Cell and Molecular Biology

Volumn 33, Issue 6, 2005, Pages 589-600

  Russo, Patrizia ^a   Catassi, Alessia ^b   Cesario, Alfrede ^b   Imperatori, Andrea ^b   Rotolo, Nicola ^b   Fini, Massimo ^b   Granone, Pierluigi ^b   Dominioni, Lorenzo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Apoptosis; Bronchial epithelial cells; Hexavalent chromium; p53; PUMA

Indexed keywords

CARCINOGEN; CASPASE 3; CHROMIC ACID; CHROMIUM; CYTOCHROME C; LIPOCORTIN 5; PROTEIN BAX; PROTEIN P53;

ALKALINE ELUTION ASSAY; APOPTOSIS; ARTICLE; ASSAY; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CANCER CELL CULTURE; CELL CULTURE; CELL STRAIN H358; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GEL ELECTROPHORESIS; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL CARCINOMA; NOXA GENE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; P53 UPREGULATED MODULATOR OF APOPTOSIS GENE; SIGNAL TRANSDUCTION; STAINING; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; BRONCHI; CARCINOGENS, ENVIRONMENTAL; CASPASE 3; CASPASES; CHROMIUM; CYTOCHROMES C; DNA DAMAGE; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 28644443748     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2005-0213OC     Document Type: Article

References (46)

1. IARC. Chromium, nickel and welding. IARC Monogr Eval Carcinog Risks Hum 1990;49:1-648.
2. Hayes RB. Review of occupational epidemiology of chromium chemicals and respiratory cancer. Sci Total Environ 1998;71:331-339.
3. Gibb HJ, Lees PS, Pinsky PF, Rooney BC. Lung cancer among workers in chromium chemical production. AM J Ind Med 2000;38:115-126.
4. Luippold RS, Mundt KA, Austin RP, Liebig E, Panko J, Crump C, Crump K, Proctor D. Lung cancer mortality among chromate production workers. Occup Environ Med 2003;60:451-457.
5. Lurie P, Wolfe SM. Continuing exposure to hexavalent chromium, a known lung carcinogen: an analysis of OSHA compliance inspections, 1990-2000. Am J Ind Med 2002;42:378-383.
6. Langard S. One hundred years of chromium and cancer: a review of epidemiological evidence and selected case reports. Am J Ind Med 1990;17:189-215.
7. Nurminen M. On the carcinogenicity risk assessment of chromium compounds. Am J Ind Med 2004;45:308-309.
8. +/-) anti-7beta, 8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene-induced cytotoxicity and mutagenicity in mammalian cells through its inhibitory effect on nucleotide excision repair. Biochemistry 2004;43:14282-14289.
9. De Flora S, Bagnasco M, Serra D, Zanacchi P. Genotoxicity of chromium compounds. Mutat Res 1990;278:99-172.
10. Costa M. Toxicity and carcinogenicity of Cr(VI) in animal models and humans. Crit Rev Toxicol 1997;27:431-442.
11. O'Brien TJ, Ceryak S, Patierno SR. Complexities of chromium carcinogenesis: role of cellular response, repair and recovery mechanisms. Mutat Res 2003;533:3-36.
12. Dayan AD, Paine AJ. Mechanisms of chromium toxicity, carcinogenicity and allerginicity: review of the literature from 1985 to 2000. Hum Exp Toxicol 2001;20:439-451.
13. Petrilli FL, Camoirano A, Bennicelli C, Zanacchi P, Astengo M, De Flora S. Specificity and inducibility of the metabolic reduction of chromium(VI) mutagenicity by subcellular fractions of rat tissues. Cancer Res 1985;45:3179-3187.
14. Tsapakos MJ, Hampton TH, Wetterhahn KE. Chromium (VI)-induced DNA lesions and chromium distribution in rat kidney, liver and lung. Cancer Res 1983;43:5662-5667.
15. Voitkun V, Zhitkovich A, Costa M. Cr(III)-mediated cross-links of glutathione or amino acids to the DNA phosphate backbone are mutagenic in human cells. Nucleic Acids Res 1998;26:2024-2030.
16. Bridgewater LC, Manning FC, Patierno SR. Arrest of replication by mammalian DNA polymerases alpha and beta caused by chromium-DNA lesions. Mol Carcinog 1998;23:201-206.
17. Wakeman TP, Kim WJ, Callens S, Chiu A, Brown KD, Xu B. The ATM-SMC1 pathway is essential for activation of the chromium[VI]-induced S-phase checkpoint. Mutat Res 2004;554:241-251.
18. Sancar A. DNA excision repair. Annu Rev Biochem 1996;65:43-81.
19. Trombino S, Cesario A, Margaritora S, Granone P, Motta G, Falugi C, Russo P. Alpha 7-nicotinic acetylcholine receptors affect growth regulation of human mesotelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004;64:135-145.
20. Sugiyama M, Tsuzuki K, Haramaki N. DNA single-strand breaks and cytotoxicity induced by sodium chromate(VI) in hydrogen peroxide-resistant cell lines. Mutat Res 1993;299:95-102.
21. Russo P, Catassi A, Malacarne D, Margaritora S, Cesario A, Festi L, Mule A, Ferri L, Granone P. Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells. Cancer 2005;103:1503-1518.
22. Russo P, Arzani D, Trombino S, Falugi C. c-myc Down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor. J Pharmacol Exp Ther 2003;304:37-47.
23. Vikhanskaya F, Falugi C, Valente P, Russo P. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int J Cancer 2002;97:732-739.
24. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995;270:1894-1898.
25. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-2949.
26. Wang J, Ladrech S, Pujol R, Brabet P, Van De Water TR, Fuel JL. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 2004;64:9217-9224.
27. Ullmannova V, Haskovec C. Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2. Neoplasma 2004;51:175-180.
28. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-694.
29. Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001;98:11318-11323.
30. Coates PJ, Lorimore SA, Wright EG. Cell and tissue responses to genotoxic stress. J Pathol 2005;205:221-235.
31. O'Reilly MA, Staversky RJ, Watkins RH, Reed CK, de Mesy Jensen KL, Finkelstein JN, Keng PC. The Cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress. Am J Respir Cell Mol Biol 2001;24:703-710.
32. D'Agostini F, Izzotti A, Bennicelli C, Camoirano A, Tampa E, De Flora S. Induction of apoptosis in the lung but not in the liver of rats receiving intra-tracheal instillations of chromium(VI). Carcinogenesis 2002;23: 587-593.
33. Wang S, Shi X. Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Carcinogenesis 2001;22:757-762.
34. Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW, Chen SL. Transcriptional repression of p21 ((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site. Biochem Biophys Res Commun 2000;270:303-310.
35. Hirose T, Kondo K, Takahashi Y, Ishikura H, Fujino H, Tsuyuguchi M, Hashimoto M, Yokose T, Mukai K, Kodama T, et al. Frequent micro-satellite instability in lung cancer from chromate-exposed workers. Mol Carcinog 2002;33:172-180.
36. Carlisle DL, Pritchard DE, Singh J, Owens BM, Blankenship LJ, Orenstein JM, Patierno SR. Apoptosis and P53 induction in human lung fibroblasts exposed to chromium (VI): effect of ascorbate and tocopherol. Toxicol Sci 2000;55:60-68.
37. Higenbottam T, Kuwano K, Nemery B, Fujita Y. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 2004;91:S31-S37.
38. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237.
39. Bardales RH, Xie SS, Schaefer RF, Hsu SM. Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am J Pathol 1996;149:845-852.
40. Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM, Dubois RM, Ladas G. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003;125:1321-1327.
41. Matthay MA. Function of the alveolar epithelial barrier under pathologic conditions. Chest 1994;105:67S-74S.
42. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-682.
43. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003;100:1931-1936.
44. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004;24:6728-6741.
45. Chow TC, Talalay P. A simple generalized equation for the analysis of multipleinhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977;252:6438-6442.
46. Chow TC, Talalay P. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115:207-216.